Search Results - "Collinson, F."

Long-term follow-up of the Medical Research Council CLASICC trial of conventional versus laparoscopically assisted resection in colorectal cancer by Green, B. L., Marshall, H. C., Collinson, F., Quirke, P., Guillou, P., Jayne, D. G., Brown, J. M.

“…Background: Laparoscopic resection is used widely in the management of colorectal cancer; however, the data on long‐term outcomes, particularly those related…”
Get full text

Optimal treatment of early-stage ovarian cancer by Collinson, F., Qian, W., Fossati, R., Lissoni, A., Williams, C., Parmar, M., Ledermann, J., Colombo, N., Swart, A.

“…There is no clear consensus regarding systemic treatment of early-stage ovarian cancer (OC). Clinical trials are challenging because of the relatively low…”
Get full text

PRISM: A randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma by Collinson, F., Brown, S., Buckley, H., Ainsworth, G., Howard, H., Poad, H., Carr, G., Banks, R.E., Brown, J., Velikova, G., Larkin, J., Nathan, P., Powles, T.B., Vasudev, N.S.

Get full text

Designing phase II trials in cancer: a systematic review and guidance by Brown, S R, Gregory, W M, Twelves, C J, Buyse, M, Collinson, F, Parmar, M, Seymour, M T, Brown, J M

“…Background: Literature reviews of cancer trials have highlighted the need for better understanding of phase II statistical designs. Understanding the key…”
Get full text

The Practicalities Involved and Lessons Learned in the Transition from Central to Local Radiology Reporting in the Context of a Seamless Phase II/III Clinical Trial by Trainor, S, Wah, T, Ralph, C, McParland, L, Gregory, W, Brown, J, Best, E, Handforth, C, Chan, K, Cook, H, Hiley, V, Oughton, J, Collinson, F

Get full text

The SABRTooth feasibility trial protocol: a study to determine the feasibility and acceptability of conducting a phase III randomised controlled trial comparing stereotactic ablative radiotherapy (SABR) with surgery in patients with peripheral stage I non-small cell lung cancer (NSCLC) considered to be at higher risk of complications from surgical resection by Snee, M P, McParland, L, Collinson, F, Lowe, C M, Striha, A, Baldwin, D R, Naidu, B, Sebag-Montefiore, D, Gregory, W M, Bestall, J, Hewison, J, Hinsley, S, Franks, K

“…Stage I non-small cell lung cancer (NSCLC) is potentially curable, and surgery is considered to be the standard of care for patients with good performance…”
Get full text

Long-term Survival and Occasional Regression of Distant Melanoma Metastases after Adrenal Metastasectomy by Collinson, F. J., Lam, T. K., Bruijn, W. M. J., de Wilt, J. H. W., Lamont, M., Thompson, J. F., Kefford, R. F.

“…Background Human melanoma cells express high-affinity glucocorticoid receptors, and adrenalectomy has been shown to have antimelanoma effects in animal models…”
Get full text

Erratum to: The SABRTooth feasibility trial protocol: a study to determine the feasibility and acceptability of conducting a phase III randomised controlled trial comparing stereotactic ablative radiotherapy (SABR) with surgery in patients with peripheral stage I non-small cell lung cancer (NSCLC) considered to be at higher risk of complications from surgical resection by Snee, M P, McParland, L, Collinson, F, Lowe, C M, Striha, A, Baldwin, D R, Naidu, B, Sebag-Montefiore, D, Gregory, W M, Bestall, J, Hewison, J, Hinsley, S, Franks, K N

“…[This corrects the article DOI: 10.1186/s40814-016-0046-2.]…”
Get full text

1476P Is it worth adding concurrent chemo-radiotherapy or radiotherapy on the top of neoadjuvant chemotherapy in the management of borderline resectable and locally advanced pancreatic adenocarcinoma? A systematic review by Saha, A., Wadsley, J., Sirohi, B., Goody, R., Ulahannan, D., Wilson, D., Collinson, F., Anthony, A.

Get full text

P18.40.B SET UP AND RECRUITMENT TO A RANDOMISED CONTROLLED TRIAL OF MEDICINAL CANNABINOIDS IN RECURRENT GLIOBLASTOMA - THE ARISTOCRAT TRIAL by Savage, J, Mant, R, Kirkham, A, Buckle, P, Banks, E, Meade, S, Boele, F, Williams, M, Collinson, F, Billingham, C, Short, S C

“…Abstract BACKGROUND ARISTOCRAT is a unique, randomised, double-blind, placebo-controlled phase II trial of cannabinoids (nabixomols) alongside temozolomide in…”
Get full text

P11.64.A Long-term follow up and translational data from the ReoGlio phase Ib trial of GM-CSF and intravenous pelareorep (Reovirus) alongside standard of care in GBM by Short, S, Kendall, J, West, E, Chalmers, A, McBain, C, Melcher, A, Collinson, F, Phillip, R, Brown, S, Samson, A

“…Abstract BACKGROUND We previously reported safety data from a phase Ib, open-label study of intravenous oncolytic virus pelareorep with GM-CSF alongside…”
Get full text

P-126 Markers of tumour inflammation are prognostic for overall survival in patients with advanced pancreatic ductal adenocarcinoma receiving FOLFIRINOX chemotherapy by Appleyard, J., Kamposioras, K., Papaxoinis, G., Collinson, F., Ahmad, U., Wright, F., Damyanova, I., Razzaq, M., Anthoney, A.

Get full text

431P The FOCUS4-N trial results and individual patient data meta-analysis (IPDM) of maintenance therapy versus active monitoring for patients with metastatic colorectal cancer (mCRC) by Adams, R.A., Fisher, D.J., Graham, J., Seligmann, J., Seymour, M., Kaplan, R.S., Yates, E., Richman, S., Quirke, P., Butler, R., Brown, E., Collinson, F., Falk, S., Wilson, R., Brown, L.C., Maughan, T.

Get full text

382O Inhibition of WEE1 is effective in TP53 and RAS mutant metastatic colorectal cancer (mCRC): A randomised phase II trial (FOCUS4-C) comparing adavosertib (AZD1775) with active monitoring by Seligmann, J., Fisher, D.J., Brown, L.C., Adams, R., Graham, J., Quirke, P., Richman, S., Butler, R., Domingo, E., Blake, A., Braun, M., Collinson, F., Jones, R., Brown, E., De Winton, E., Humphies, T., Kaplan, R., Wilson, R., Seymour, M., Maughan, T.

Get full text

LBA28 STAR: A randomised multi-stage phase II/III trial of standard first-line therapy (sunitinib or pazopanib) comparing temporary cessation with allowing continuation, in the treatment of locally advanced and/or metastatic renal Cancer (RCC) by Brown, J.E., Royle, K-L., Ralph, C., Meads, D., Martin, A., Howard, H., Linsley, C., Swain, J., Powles, T.B., Jones, R., Eisen, T., Maraveyas, A., Griffiths, R., Din, O., Goh, V., Wah, T., Selby, P., Hewison, J., Brown, J., Collinson, F.

Get full text

LBA29 Nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced renal cell carcinoma: A randomized phase II trial (PRISM) by Vasudev, N.S., Ainsworth, G., Brown, S., Pickering, L., Waddell, T.S., Fife, K., Griffiths, R., Sharma, A., Katona, E., Howard, H., Velikova, G., Maraveyas, A., Brown, J.E., Venugopal, B., Patel, P., Jain, A., Symeonides, S., Nathan, P.D., Collinson, F., Powles, T.B.

Get full text

Role of neoadjuvant treatment in borderline and locally advanced pancreatic ductal adenocarcinoma: the leeds experience by Suresh, N., Smith, A., Young, A., Anthoney, A., Khokhar, U., Pine, J., Goodey, R., Collinson, F., Ulahannan, D.

Get full text

Single intravenous preoperative administration of the oncolytic virus Pexa-Vec to prime anti-tumour immunity by Samson, A., West, E., Turnbull, S., Scott, K., Tidswell, E., Kingston, J., Johnpulle, M., Bendjama, K., Stojkowitz, N., Lusky, M., Toogood, G., Twelves, C.J., Ralph, C., Anthoney, A., Melcher, A., Collinson, F.

Get full text

1213PSingle intravenous preoperative administration of the oncolytic virus Pexa-Vec to prime anti-tumour immunity by Samson, A, West, E, Turnbull, S, Scott, K, Tidswell, E, Kingston, J, Johnpulle, M, Bendjama, K, Stojkowitz, N, Lusky, M, Toogood, G, Twelves, C J, Ralph, C, Anthoney, A, Melcher, A, Collinson, F

“…Abstract Background Oncolytic viruses constitute a promising modality of cancer therapy. Pexa-Vec, a Thymidine Kinase-Deactivated Vaccinia Virus expressing…”
Get full text

1213P - Single intravenous preoperative administration of the oncolytic virus Pexa-Vec to prime anti-tumour immunity by Samson, A., West, E., Turnbull, S., Scott, K., Tidswell, E., Kingston, J., Johnpulle, M., Bendjama, K., Stojkowitz, N., Lusky, M., Toogood, G., Twelves, C.J., Ralph, C., Anthoney, A., Melcher, A., Collinson, F.

“…Oncolytic viruses constitute a promising modality of cancer therapy. Pexa-Vec, a Thymidine Kinase-Deactivated Vaccinia Virus expressing GM-CSF, has been shown…”
Get full text